News

They have a knack for increasing their dividends even when facing challenges.

Analysts keep raising their price targets on this 54-year dividend raiser. Here are the reasons behind the newfound confidence.

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.

Abbott Laboratories (NYSE:ABT) reached a US$385 million settlement tied to the 2022 infant formula recall and Sturgis plant shutdown. The agreement resolves civil claims from families, states, and other plaintiffs alleging product safety failures and gaps in compliance with federal standards. The settlement follows U.S. Department of Justice and multi state investigations into Abbott's infant formula operations, with no admission of liability. This civil resolution of Abbott's 2022 formula...

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

Abbott Laboratories (NYSE:ABT) has agreed to pay more than $384 million to resolve U.S. Justice Department allegations that it knowingly produced infant formula in potentially contaminated environments at its Michigan and Arizona facilities, including allegations of inadequate testing and failure to disclose positive contamination tests to regulators. The settlement resolves civil claims without an admission […]

Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta

Texas is no longer treating every proposed data center as an automatic addition to the grid. On August 3, Governor Greg Abbott ordered an audit of projects moving through ERCOT’s interconnection process, which contained more than 474 gigawatts of requests, over five times the state’s record peak demand. ERCOT began issuing verification requests on September […]

Abbott Laboratories will pay $385 million to resolve claims tied to an investigation of contamination at a baby formula factory in Sturgis, Michigan, the largest in the country, which led to the supply shortages in 2022. Problems at the facility prompted a lawsuit by the Justice Department and recall of powdered infant formula at the facility. The recall covered several infant formula brands, including Similac, and squeezed inventory that had already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

Some federal prosecutors believed there was enough evidence to bring criminal charges, but Justice Department leadership opted for a civil settlement.

Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.

Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

NVST vs. ABT: Which Stock Is the Better Value Option?

FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close.

MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.

BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.

Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.